Neulasta
Manufacturing · Indiana, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 68376, Indianapolis, Indiana, 462...Website
www.neulasta.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Neulasta
Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. In a pivotal clinical trial, in patients with nonmyeloid malignancies undergoing myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia, treatment with Neulasta was shown to significantly reduce the incidence of febrile neutropenia. Neulasta is administered by manual injection and is also available via the NeulastaOnprokit, which was approved by theFDAin 2014 and includes a specially designed, single-use prefilled syringe co-packaged with an on-body injector for Neulasta.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neulasta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Neulasta, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Neulasta recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Neulasta
Product Launch: Get notified when Neulasta launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Neulasta has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Neulasta has new funding data
Click to see if Neulasta had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Neulasta is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Neulasta as Masked Content
Find 3 more new buyers
Compare Similar Companies to Neulasta
Compare insights from companies similar to Neulasta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neulasta
<$5M
11-50
Private
-
2015
N/A
Company Profile Activity
Activity Insights
Neulasta is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neulasta is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neulasta.
Neulasta Tech Stack
A closer look at the technologies used by Neulasta
See more technologies
Neulasta News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neulasta
Sign Up For FreeTo access detailed company insights
Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for h... Read More
